Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in Idiopathic Pulmonary Fibrosis
NCT05321069Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 37
01
Overview
A Phase 3 trial of nerandomilast in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Oct 2022; status: completed.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05321069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321069.